Scott D. Boden
Research Subjects
Scott D. Boden has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
George J. Martin
3 shared publicationsHarvinder S. Sandhu
2 shared publicationsBill McKay
1 shared publicationChantrice Rogers
Orthopaedics, Emory University School of Medicine, Decatur, GA
1 shared publicationChristopher Damien
1 shared publicationD. Greg Anderson
1 shared publication
Latest Publications
- 10 May 2021
- Published by Wolters Kluwer Health in Spine
- Vol. 46 (22) , 1534
Commentary Regarding: “A Case-control Study of Major Genetic Pre-disposition Risk Alleles in Developing DDD in the Northeast US Population: Effects of Gene-gene Interactions”
An abstract is unavailable. This article is available as a PDF only.
- 10 May 2021
- Published by Wolters Kluwer Health in Spine
- Vol. 46 (22) , 1534
Commentary Regarding: “A Case-control Study of Major Genetic Pre-disposition Risk Alleles in Developing DDD in the Northeast US Population: Effects of Gene-gene Interactions”
An abstract is unavailable. This article is available as a PDF only.
- 23 December 2018
- Published by Springer Nature
- p. 341-348
Biological Enhancers of Fusion
- 1 April 2010
- Published by Wolters Kluwer Health in Spine
- Vol. 35 (8) , 845-847
2009 ISSLS Presidential Address
- 1 April 2010
- Published by Wolters Kluwer Health in Spine
- Vol. 35 (8) , 845-847
2009 ISSLS Presidential Address
- Open Access
- 31 December 2006
- Published by Elsevier in Molecular Therapy
- Vol. 13, S220
571. Increasing BMP Responsiveness in Human Mesenchymal Stem Cells In-Vitro by Delivery of the Osteoinductive LMP-1 Gene
- 31 December 2006
- Published by Elsevier in Molecular Therapy
- Vol. 13, S220
Open Access571. Increasing BMP Responsiveness in Human Mesenchymal Stem Cells In-Vitro by Delivery of the Osteoinductive LMP-1 Gene
- 1 August 2002
- Published by Wolters Kluwer Health in Spine
- Vol. 27 (Supplement) , S49
Summary Statement: Clinical BMP Programs
- 1 August 2002
- Published by Wolters Kluwer Health in Spine
- Vol. 27 (Supplement) , S49
Summary Statement: Clinical BMP Programs
- 1 August 2000
- Published by SAGE Publications in Tissue Engineering
- Vol. 6 (4) , 383-399
Biology of Lumbar Spine Fusion and Use of Bone Graft Substitutes: Present, Future, and Next Generation
Posterolateral lumbar spine arthrodesis is a commonly performed procedure, yet the biology of healing is poorly understood. Nonunion, or failure to achieve a solid bony fusion, occurs in up to 40% of patients. We first developed and validated a rabbit model to characterize the healing process by measuring macroscopic parameters, microscopic parameters, and gene expression. We found that presently available osteoconductive and weakly osteoinductive materials were insufficient to replace autografts, but could in some cases serve as bone graft extenders. In contrast, two osteoinductive growth factors currently in development could replace autograft in non-human primates and in humans, but may be limited by the high dose required, carrier variability, and high cost. We identified, cloned, and sequenced a novel complementary DNA (cDNA) encoding for an intracellular protein LMP-1, which is expressed during the first few hours of osteoblast differentiation. LMP-1 expression is able to induce many BMPs, their receptors, and other bone growth factors. Local implantation of bone marrow cells transfected with LMP-1 cDNA induced spine fusion in 100% of sites tested; no bone formed at the control sites without LMP-1. This strategy of local gene therapy may provide a basis for the next generation of bone graft substitutes.
- 1 August 2000
- Published by SAGE Publications in Tissue Engineering
- Vol. 6 (4) , 383-399
Biology of Lumbar Spine Fusion and Use of Bone Graft Substitutes: Present, Future, and Next Generation
Posterolateral lumbar spine arthrodesis is a commonly performed procedure, yet the biology of healing is poorly understood. Nonunion, or failure to achieve a solid bony fusion, occurs in up to 40% of patients. We first developed and validated a rabbit model to characterize the healing process by measuring macroscopic parameters, microscopic parameters, and gene expression. We found that presently available osteoconductive and weakly osteoinductive materials were insufficient to replace autografts, but could in some cases serve as bone graft extenders. In contrast, two osteoinductive growth factors currently in development could replace autograft in non-human primates and in humans, but may be limited by the high dose required, carrier variability, and high cost. We identified, cloned, and sequenced a novel complementary DNA (cDNA) encoding for an intracellular protein LMP-1, which is expressed during the first few hours of osteoblast differentiation. LMP-1 expression is able to induce many BMPs, their receptors, and other bone growth factors. Local implantation of bone marrow cells transfected with LMP-1 cDNA induced spine fusion in 100% of sites tested; no bone formed at the control sites without LMP-1. This strategy of local gene therapy may provide a basis for the next generation of bone graft substitutes.
- Top Cited Papers
- 1 February 2000
- Published by Wolters Kluwer Health in Spine
- Vol. 25 (3) , 376-381
The Use of rhBMP-2 in Interbody Fusion Cages
A prospective randomized controlled human clinical pilot trial. To determine the feasibility of using rhBMP-2/collagen as a substitute for autogenous bone graft inside interbody fusion cages to achieve arthrodesis in humans. Preclinical studies have shown rhBMP-2 to be an effective substitute for autogenous bone graft, but there are no studies to date documenting such efficacy for human spine fusion. Fourteen patients with single-level lumbar degenerative disc disease refractory to nonoperative management were randomized to receive lumbar interbody arthrodesis with a tapered cylindrical threaded fusion cage filled with rhBMP-2/collagen sponge or autogenous iliac crest bone. Patients were evaluated with radiographs, sagittally reformatted computed tomography scans, and Short Form-36 and Oswestry outcome questionnaires. All 11 patients who received rhBMP-2 were judged by three independent radiologists to have solid fusions (at 6, 12, and 24 months postimplantation), whereas only 2 of the 3 control patients, who received the standard treatment of autogenous iliac crest bone, were deemed to be fused. The Oswestry Disability Questionnaire scores of the rhBMP-2 group improved sooner (after 3 months) than those of the autograft group, with both groups demonstrating similar improvement at 6 months. Short Form 36 scores continued to improve up to 24 months. The arthrodesis was found to occur more reliably in patients treated with rhBMP-2-filled fusion cages than in controls treated with autogenous bone graft, although the sample size was limited. There were no adverse events related to the rhBMP-2 treatment. This study is one of the first to show consistent and unequivocal osteoinduction by a recombinant growth factor in-humans.
- 1 February 2000
- Published by Wolters Kluwer Health in Spine
- Vol. 25 (3) , 376-381
Top Cited PapersThe Use of rhBMP-2 in Interbody Fusion Cages
A prospective randomized controlled human clinical pilot trial. To determine the feasibility of using rhBMP-2/collagen as a substitute for autogenous bone graft inside interbody fusion cages to achieve arthrodesis in humans. Preclinical studies have shown rhBMP-2 to be an effective substitute for autogenous bone graft, but there are no studies to date documenting such efficacy for human spine fusion. Fourteen patients with single-level lumbar degenerative disc disease refractory to nonoperative management were randomized to receive lumbar interbody arthrodesis with a tapered cylindrical threaded fusion cage filled with rhBMP-2/collagen sponge or autogenous iliac crest bone. Patients were evaluated with radiographs, sagittally reformatted computed tomography scans, and Short Form-36 and Oswestry outcome questionnaires. All 11 patients who received rhBMP-2 were judged by three independent radiologists to have solid fusions (at 6, 12, and 24 months postimplantation), whereas only 2 of the 3 control patients, who received the standard treatment of autogenous iliac crest bone, were deemed to be fused. The Oswestry Disability Questionnaire scores of the rhBMP-2 group improved sooner (after 3 months) than those of the autograft group, with both groups demonstrating similar improvement at 6 months. Short Form 36 scores continued to improve up to 24 months. The arthrodesis was found to occur more reliably in patients treated with rhBMP-2-filled fusion cages than in controls treated with autogenous bone graft, although the sample size was limited. There were no adverse events related to the rhBMP-2 treatment. This study is one of the first to show consistent and unequivocal osteoinduction by a recombinant growth factor in-humans.
- 1 February 1999
- Published by Wolters Kluwer Health in Spine
- Vol. 24 (4) , 320-327
The Use of Coralline Hydroxyapatite With Bone Marrow, Autogenous Bone Graft, or Osteoinductive Bone Protein Extract for Posterolateral Lumbar Spine Fusion
A posterolateral lumbar arthrodesis animal model using coralline hydroxyapatite as a bone graft substitute. To determine the effectiveness of coralline hydroxyapatite as a bone graft substitute for lumbar spine fusion when used with bone marrow, autogenous bone graft, or an osteoinductive bone protein extract. Coralline hydroxyapatite is commonly used as a bone graft substitute in metaphysial defects but its use in a more challenging healing environment such as the posterolateral spine remains controversial. There are no published animal studies in which the use of coralline hydroxyapatite has been evaluated in a posterolateral lumbar arthrodesis model. Single-level posterolateral lumbar arthrodesis was performed at L5-L6 in 48 adult New Zealand White rabbits. Rabbits were assigned to one of three groups based on the graft material they received: 3.0 mL coralline hydroxyapatite 1.5 mL plus bone marrow; 1.5 mL coralline hydroxyapatite plus 1.5 mL autogenous iliac crest bone; and, 3.0 mL coralline hydroxyapatite plus 500 μg bovine-derived osteoinductive bone protein extract on each side. Rabbits were killed after 2, 5, or 10 weeks, and the spines were excised and evaluated by manual palpation, radiographs, tensile biomechanical testing, and nondecalcified histology. Fusions were assessed by manual palpation at 5 weeks for comparisons among the three groups of graft materials. The coralline hydroxyapatite used with bone marrow produced no solid fusions (0/14). When combined with an equal amount of autogenous iliac crest bone, coralline hydroxyapatite resulted in solid fusion in 50% (7/14) of the rabbits (P < 0.05). When combined with the osteoinductive growth factor extract, the coralline hydroxyapatite resulted in solid fusion in 100% (11/11) of the rabbits (P < 0.05). The fusion masses in the growth factor group were significantly stronger (1.8 ± 0.2 vs. 1.3 ± 0.1; P = 0.02) and stiffer (1.5 ± 0.2 vs. 1.2 ± 0.1, P = 0.04) based on tensile testing to failure when normalized to the adjacent unfused level. These data indicate that coralline hydroxyapatite with bone marrow was not an acceptable bone graft substitute for posterolateral spine fusion. When combined with autogenous iliac crest bone graft-coralline hydroxyapatite served as a graft extender yielding results comparable to those obtained with autograft alone. Coralline hydroxyapatite served as an excellent carrier for the bovine osteoinductive bone protein extract yielding superior results to those obtained with autograft or bone marrow.
- 1 February 1999
- Published by Wolters Kluwer Health in Spine
- Vol. 24 (4) , 320-327
The Use of Coralline Hydroxyapatite With Bone Marrow, Autogenous Bone Graft, or Osteoinductive Bone Protein Extract for Posterolateral Lumbar Spine Fusion
A posterolateral lumbar arthrodesis animal model using coralline hydroxyapatite as a bone graft substitute. To determine the effectiveness of coralline hydroxyapatite as a bone graft substitute for lumbar spine fusion when used with bone marrow, autogenous bone graft, or an osteoinductive bone protein extract. Coralline hydroxyapatite is commonly used as a bone graft substitute in metaphysial defects but its use in a more challenging healing environment such as the posterolateral spine remains controversial. There are no published animal studies in which the use of coralline hydroxyapatite has been evaluated in a posterolateral lumbar arthrodesis model. Single-level posterolateral lumbar arthrodesis was performed at L5-L6 in 48 adult New Zealand White rabbits. Rabbits were assigned to one of three groups based on the graft material they received: 3.0 mL coralline hydroxyapatite 1.5 mL plus bone marrow; 1.5 mL coralline hydroxyapatite plus 1.5 mL autogenous iliac crest bone; and, 3.0 mL coralline hydroxyapatite plus 500 μg bovine-derived osteoinductive bone protein extract on each side. Rabbits were killed after 2, 5, or 10 weeks, and the spines were excised and evaluated by manual palpation, radiographs, tensile biomechanical testing, and nondecalcified histology. Fusions were assessed by manual palpation at 5 weeks for comparisons among the three groups of graft materials. The coralline hydroxyapatite used with bone marrow produced no solid fusions (0/14). When combined with an equal amount of autogenous iliac crest bone, coralline hydroxyapatite resulted in solid fusion in 50% (7/14) of the rabbits (P < 0.05). When combined with the osteoinductive growth factor extract, the coralline hydroxyapatite resulted in solid fusion in 100% (11/11) of the rabbits (P < 0.05). The fusion masses in the growth factor group were significantly stronger (1.8 ± 0.2 vs. 1.3 ± 0.1; P = 0.02) and stiffer (1.5 ± 0.2 vs. 1.2 ± 0.1, P = 0.04) based on tensile testing to failure when normalized to the adjacent unfused level. These data indicate that coralline hydroxyapatite with bone marrow was not an acceptable bone graft substitute for posterolateral spine fusion. When combined with autogenous iliac crest bone graft-coralline hydroxyapatite served as a graft extender yielding results comparable to those obtained with autograft alone. Coralline hydroxyapatite served as an excellent carrier for the bovine osteoinductive bone protein extract yielding superior results to those obtained with autograft or bone marrow.
- 1 September 1997
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 41 (3) , 746
The Genetic Expression of Bone Morphogenetic Proteins (BMP) During Experimental Lumbar Spinal Fusion
Introduction. BMPs may be important in the healing of spinal fusions because the addition of BMP-2 to experimental spinal fusions has been shown to increase the rate of solid fusion and fusion mass size. The manner in which BMPs enhance spinal fusions is still unknown; one method to determine their function may be to examine their gene expression pattern in healing spinal fusions. We have previously demonstrated the genetic expression pattern of various bone matrix proteins in a rabbit model of posterolateral lumbar spinal fusion. In the current study, we attempted to define the spatial and temporal genetic expression patterns of various BMPs in this model. In addition, the effects of the addition of BMP-2 to lumbar fusion on BMP gene expression patterns were also examined.
- 1 September 1997
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 41 (3) , 746
The Genetic Expression of Bone Morphogenetic Proteins (BMP) During Experimental Lumbar Spinal Fusion
Introduction. BMPs may be important in the healing of spinal fusions because the addition of BMP-2 to experimental spinal fusions has been shown to increase the rate of solid fusion and fusion mass size. The manner in which BMPs enhance spinal fusions is still unknown; one method to determine their function may be to examine their gene expression pattern in healing spinal fusions. We have previously demonstrated the genetic expression pattern of various bone matrix proteins in a rabbit model of posterolateral lumbar spinal fusion. In the current study, we attempted to define the spatial and temporal genetic expression patterns of various BMPs in this model. In addition, the effects of the addition of BMP-2 to lumbar fusion on BMP gene expression patterns were also examined.
- 1 September 1997
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 41 (3) , 746
Laparoscopic Anterior Spinal Arthrodesis with rhBMP-2 in a Titanium Interbody Threaded Cage
- 1 September 1997
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 41 (3) , 746
Laparoscopic Anterior Spinal Arthrodesis with rhBMP-2 in a Titanium Interbody Threaded Cage